Zydus Lifesciences Wins USFDA Approval for Diabetes Drug Dapagliflozin

Zydus Lifesciences announced on April 8, 2026, that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Dapagliflozin Tablets in 5 mg and 10 mg strengths. This approval grants Zydus eligibility for 180 days of shared generic drug exclusivity in the competitive U.S. market. The company plans to manufacture these tablets at its Special Economic Zone (SEZ) facility in Ahmedabad, Gujarat.

Significance for Zydus

The USFDA final approval allows Zydus to legally market and sell its Dapagliflozin tablets within the significant United States pharmaceutical market. Securing 180 days of shared generic drug exclusivity provides a crucial competitive advantage, enabling Zydus to establish an initial market presence before broader generic competition intensifies. This move is expected to strengthen the company's position in the lucrative diabetes treatment segment.

About Dapagliflozin

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This class of medication is prescribed to improve blood sugar control in adults diagnosed with type 2 diabetes.

Manufacturing and Past Approvals

Zydus has been actively pursuing approvals for its generic diabetes treatments. The company previously secured tentative approvals for these 5 mg and 10 mg Dapagliflozin tablets in February 2026, with manufacturing also slated for its Ahmedabad SEZ facility. These approvals follow a period where Indian pharmaceutical manufacturers, including Zydus, have faced increased scrutiny from the USFDA regarding manufacturing practices at various sites.

Market Landscape and Competition

The U.S. market for Dapagliflozin tablets is highly competitive. Zydus's approval comes shortly after Alembic Pharmaceuticals secured similar final USFDA approval and 180-day shared exclusivity for its Dapagliflozin tablets on April 7, 2026. Lupin Limited also holds tentative approvals for the drug. The 'shared' nature of the exclusivity means Zydus will compete with other eligible generic manufacturers during this period, potentially moderating the full benefit of the exclusivity. Sun Pharmaceutical Industries is noted for its substantial presence in U.S. diabetes and cardiovascular drug markets.

Key Market Data

In the United States, Dapagliflozin tablets generated annual sales of $10.2 billion as of February 2026. As of December 31, 2025, Zydus Lifesciences' group had accumulated a total of 436 approvals and filed 505 Abbreviated New Drug Applications (ANDAs) since FY 2003-04.